403 related articles for article (PubMed ID: 30015847)
1. LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling.
Xiao Q; Dong M; Cheng F; Mao F; Zong W; Wu K; Wang H; Xie R; Wang B; Lei T; Guo D
Int J Oncol; 2018 Sep; 53(3):1069-1082. PubMed ID: 30015847
[TBL] [Abstract][Full Text] [Related]
2. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
3. Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2.
Xiao Q; Tan Y; Guo Y; Yang H; Mao F; Xie R; Wang B; Lei T; Guo D
PLoS One; 2014; 9(10):e111419. PubMed ID: 25353163
[TBL] [Abstract][Full Text] [Related]
4. Lrig2-deficient mice are protected against PDGFB-induced glioma.
Rondahl V; Holmlund C; Karlsson T; Wang B; Faraz M; Henriksson R; Hedman H
PLoS One; 2013; 8(9):e73635. PubMed ID: 24023893
[TBL] [Abstract][Full Text] [Related]
5. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
Akhavan D; Pourzia AL; Nourian AA; Williams KJ; Nathanson D; Babic I; Villa GR; Tanaka K; Nael A; Yang H; Dang J; Vinters HV; Yong WH; Flagg M; Tamanoi F; Sasayama T; James CD; Kornblum HI; Cloughesy TF; Cavenee WK; Bensinger SJ; Mischel PS
Cancer Discov; 2013 May; 3(5):534-47. PubMed ID: 23533263
[TBL] [Abstract][Full Text] [Related]
6. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
[TBL] [Abstract][Full Text] [Related]
7. MiR-449a exerts tumor-suppressive functions in human glioblastoma by targeting Myc-associated zinc-finger protein.
Yao Y; Ma J; Xue Y; Wang P; Li Z; Li Z; Hu Y; Shang X; Liu Y
Mol Oncol; 2015 Mar; 9(3):640-56. PubMed ID: 25487955
[TBL] [Abstract][Full Text] [Related]
8. TRIM59 Promotes Gliomagenesis by Inhibiting TC45 Dephosphorylation of STAT3.
Sang Y; Li Y; Song L; Alvarez AA; Zhang W; Lv D; Tang J; Liu F; Chang Z; Hatakeyama S; Hu B; Cheng SY; Feng H
Cancer Res; 2018 Apr; 78(7):1792-1804. PubMed ID: 29386185
[TBL] [Abstract][Full Text] [Related]
9. Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma.
Ito H; Watari K; Shibata T; Miyamoto T; Murakami Y; Nakahara Y; Izumi H; Wakimoto H; Kuwano M; Abe T; Ono M
Cancer Res; 2020 Jan; 80(2):234-248. PubMed ID: 31723002
[TBL] [Abstract][Full Text] [Related]
10. EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma.
Gao M; Fu Y; Zhou W; Gui G; Lal B; Li Y; Xia S; Ji H; Eberhart CG; Laterra J; Ying M
Cancer Res; 2021 Jul; 81(13):3580-3592. PubMed ID: 33910930
[TBL] [Abstract][Full Text] [Related]
11. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
12. Overexpressed miR-183 promoted glioblastoma radioresistance via down-regulating LRIG1.
Fan H; Yuan R; Cheng S; Xiong K; Zhu X; Zhang Y
Biomed Pharmacother; 2018 Jan; 97():1554-1563. PubMed ID: 29793318
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro.
Wang B; Han L; Chen R; Cai M; Han F; Lei T; Guo D
Cancer Biol Ther; 2009 Jun; 8(11):1018-23. PubMed ID: 19421009
[TBL] [Abstract][Full Text] [Related]
14. Sprouty2 enhances the tumorigenic potential of glioblastoma cells.
Park JW; Wollmann G; Urbiola C; Fogli B; Florio T; Geley S; Klimaschewski L
Neuro Oncol; 2018 Jul; 20(8):1044-1054. PubMed ID: 29635363
[TBL] [Abstract][Full Text] [Related]
15. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
16. Up-regulated circular RNA hsa_circ_0067934 contributes to glioblastoma progression through activating PI3K-AKT pathway.
Xin J; Zhang XY; Sun DK; Tian LQ; Xu P
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3447-3454. PubMed ID: 31081099
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K/AKT signalling pathway.
Guan Y; He Y; Lv S; Hou X; Li L; Song J
J Drug Target; 2019 Jan; 27(1):60-66. PubMed ID: 29768063
[TBL] [Abstract][Full Text] [Related]
18. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
19. MYST1/KAT8 contributes to tumor progression by activating EGFR signaling in glioblastoma cells.
Dong Z; Zou J; Li J; Pang Y; Liu Y; Deng C; Chen F; Cui H
Cancer Med; 2019 Dec; 8(18):7793-7808. PubMed ID: 31691527
[TBL] [Abstract][Full Text] [Related]
20. Polydatin executes anticancer effects against glioblastoma multiforme by inhibiting the EGFR-AKT/ERK1/2/STAT3-SOX2/Snail signaling pathway.
Chen Y; Niu J; Li L; Li Z; Jiang J; Zhu M; Dong T; Zhang J; Shi C; Xu P; Lu Y; Jiang Y; Liu P; Chen W
Life Sci; 2020 Oct; 258():118158. PubMed ID: 32750435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
